Arca
Skip to content

Epilepsy

Drug research and approvals for epilepsy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 359 studies of epilepsy are recruiting on ClinicalTrials.gov, Health Canada has authorized 37 drug trials for it since 2013, FDA has 2 approved and 16 open orphan designations naming it, and the EU has 27 authorised medicines for it.

  • Recruiting worldwide: 359
  • Trials authorized in Canada: 37
  • FDA orphan approvals: 2
  • EU medicines: 27

Recruiting Now

Newest start dates first, of 359 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 37; search them all in Canada trials
Jun 16, 2026A parallel-group, phase 2, double-blind, placebo-controlled, randomized study of the safety and efficacy of oral av078 in participants with tuberous sclerosis…AV078AEOVIAN PHARMACEUTICALS INCOngoing
Jul 29, 2025A triple-blind, placebo-controlled, randomized clinical trial of cannabinoids for drug resistant epilepsy in adults and childrenMPL-015 (CANNABIDIOL (CBD)) / MPL-016 (DELTA-9-TETRAHYDROCANNABINOL…UNIVERSITY OF MANITOBAPending
Apr 14, 2025A phase 3, open-label study to investigate the long-term safety and efficacy of lp352 in the treatment of seizures in children and adults with developmental…BEXICASERIN (LP352)LONGBOARD PHARMACEUTICALS, INC.Ongoing
Mar 21, 2025A phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of lp352 in the treatment of…BEXICASERIN (LP352)LONGBOARD PHARMACEUTICALS, INC.Ongoing
Jan 14, 2025A pilot, triple-blind, placebo-controlled, randomized clinical trial of cannabinoids for drug resistant epilepsy in adults and childrenMPL-010 (CANNABIDIOL) / MPL-011 (DELTA-9-TETRAHYDROCANNABINOL)UNIVERSITY OF MANITOBAClosed
May 24, 2024Model-informed precision dosing (mipd) in neonates-prospective feasibility trialFOSPHENYTOIN/ ENOXAPARINTHE HOSPITAL FOR SICK CHILDRENPending
Dec 28, 2023Ferumoxytol enhanced hippocampal vascular imaging in epilepsyFERUMOXYTOLGOVERNORS OF THE UNIVERSITY OF ALBERTAOngoing
May 24, 2023A phase 3, open-label study of adjunctive ganaxolone (gnx) treatment in children and adults with tuberous sclerosis complex (tsc)-related epilepsy (trusttsc…GANAXOLONEMARINUS PHARMACEUTICALS, INC.Closed
Mar 9, 2023A randomized, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate the safety, tolerability, and efficacy of xen1101 as adjunctive therapy…AZETUKALNER (XEN1101)XENON PHARMACEUTICALS INCOngoing
Jul 8, 2022A phase 3, double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone (gnx) treatment in children and adults with tuberous sclerosis complex…GANAXOLONEMARINUS PHARMACEUTICALS, INC.Closed

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 18
Oct 7, 2016CARNEXIVReplacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following…Lundbeck LLCApproved
Jul 29, 1997DiastatFor the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require…Valeant PharmaceuticalsApproved
Oct 23, 2024antrafeninetreatment of KCNT1-related epilepsyUniSA Ventures Pty LtdDesignated
Sep 25, 2024Anti-epileptic small molecule inhibitor of KCNT1treatment of KCNT1-related EpilepsyActio BiosciencesDesignated
May 17, 2023(5R)-5-ethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopro…Treatment of progressive myoclonic epilepsy-7Autifony Therapeutics Ltd.Designated
Jan 19, 2022flunarizineTreatment of Juvenile Absence Epilepsy (JAE)Xenon Pharmaceuticals Inc.Designated
Jun 7, 2021cannabidiol oral solution (CBD-OS)Treatment of epilepsy with myoclonic-atonic seizuresJazz Pharmaceuticals Research UK LimitedDesignated
May 12, 2021flunarizineTreatment of Childhood Absence EpilepsyXenon Pharmaceuticals Inc.Designated
Dec 3, 2019brivaracetamTreatment of Juvenile Absence EpilepsyUCB, Inc.Designated
Dec 3, 2019brivaracetamTreatment of Childhood Absence EpilepsyUCB, Inc.Designated
Aug 15, 2019cannabidiolTreatment of childhood absence epilepsyBenuvia Operations LLCDesignated
Dec 14, 2017metforminTreatment of progressive myoclonus epilepsy type 2 (Lafora disease)Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER)Designated
Nov 10, 2016diazepamTreatment of selected, refractory patients with epilepsy who are on stable regimens of antiepileptic drugs (AED) and who require…Aquestive TherapeuticsDesignated
Mar 24, 2015ganaxoloneTreatment of Protocadherin 19 (PCDH19) female epilepsy.Immedica Pharma ABDesignated
Jul 24, 2013topiramate injectionTreatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being…CURx Pharmaceuticals, Inc.Designated

Medicines Authorised in the EU

Newest first; 15 of 27

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.